EGFR and cancer: Previous studies demonstrated that RHOV functions as an oncogene in LUAD, promoting cancer cell growth, metastasis, and resistance to epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor therapies [21, 22, 23].